Sickle Cell Disease Drugs Market Share

North America Market Insights

The North America market for the sickle cell disease drugs market is dominant and anticipated to hold a market share of 45.3% by 2037. Development of the healthcare infrastructure and an increased number of diagnoses led to an increased burden of incidence of sickle cell disease in North America. Quick adoption of the advanced treatment through gene therapy and the use of hydroxyurea led to better patient outcomes and quick recovery from the disease. The government support expanded, and Medicare coverage increased to more than 55%, which ensured higher accessibility for patients in the concerned market. Government intervention to regulate the price cap is not conducted in North America, which allows the market to perform a higher rate of research and development, significantly leading to market growth. Manufacturers find it easier to recover the cost of the R&D as comparison to the markets of the EU and the Asia Pacific.

The U.S. markets dominate the regional market of sickle cell disease drugs. Medicaid expansion to approximately USD 1.1 billion in 2024 resulted in the growth of market accessibility. Federal funding that estimates approximately USD 4.8 billion and almost 8.6% of the health care budget is invested in research and development for sickle cell disease. As per the mandate of the Centers for Disease Control and Prevention, new-born screening is made compulsory, that led to an increased number of diagnoses and directed the market demand for sickle cell disease drugs. More than 75% of the global SDC trials are conducted in the U.S., which leads the country to dominate in the North America region. Almost over 85% of the global gene therapy revenue is accumulated from the U.S. market through Casgevy and Lyfgenia.

Asia Pacific Market Insights

The Asia Pacific is addressed as the emerging region in the sickle cell disease drugs market and is anticipated to hold a global market share of 18.5% by 2037. According to the report of the World Health Organization, more than 75% of newborns born with sickle cell disease are addressed in India and Africa. Diagnosis level of the diseases is quite less, although advancement in the healthcare infrastructure and government initiatives is gradually expanding the early diagnosis of sickle cell disease. Government-led initiative resulted in the expansion of the treatment and raised awareness in the Asia Pacific market, which generated a significant demand for sickle cell disease drugs. Cost-effective manufacturing of the drug is conducted in the Asia Pacific market, which has made hydroxyurea the primary therapy as per a study by the WHO.

The market of sickle cell disease drugs in India is growing at a rapid pace and is anticipated to hold a regional market share of 55.7% by 2037. A higher number of patients dealing with sickle cell disease is addressed in India, that elevated the demand for advanced and affordable treatment. As per the report placed by ICMR, over 390k patients are diagnosed with sickle cell disease in India. Government expenditure expanded up to USD 1.9 billion through the National SCD Mission launched in 2023. This resulted in patient accessibility and avail the treatment for sickle cell disease. The manufacturing cost of hydroxyurea in India is USD 50 each year, which is quite low in comparison to the U.S. and other countries. More than 85% of the population depends on the generics that contain hydroxyurea.

Asia-Pacific Region: Government Investment & Policy Table for 2025- sickle cell disease drugs